<DOC>
	<DOCNO>NCT00314977</DOCNO>
	<brief_summary>2 different treatment schedule may use neoadjuvant chemotherapy breast cancer use adriamycin , cyclophosphamide taxotere . The optimal sequence- concurrent sequential- however unclear . The aim study compare efficacy tolerability neoadjuvant chemotherapy AC follow T ( adriamycin , cyclophosphamide , taxotere ) versus TAC ( upfront T ) patient large resectable locally advanced breast cancer .</brief_summary>
	<brief_title>Sequential v Upfront Intensified Neoadjuvant Chemotherapy Patients With Large Resectable Locally Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Women present large resectable locally advanced breast cancer ( T2 ≥3 cm , T3 , T4 , and/or LN positive ) Measurable disease ( breast and/or lymph node ) No prior surgery biopsy prior chemotherapy radiation therapy Age ≥18 year age ≤70 year Karnofsky Performance score ≥70 % Estrogen and/or progesterone receptor analysis perform primary tumour biopsy material In case tumor ER/PgR ³ 50 % positive , ( neo ) adjuvant hormonal therapy stead chemotherapy consider ( e.g . TEAM II study ) Her2/neu receptor analysis perform primary tumour biopsy material Adequate bone marrow function ( within 14 day prior registration ) : WBC ≥3.0 x 109/l , neutrophil ≥1.5 x 109/l , platelet ≥100 x 109/l Adequate liver function ( within 4 week prior start treatment ) : bilirubin ≤1.5 x upper limit normal ( UNL ) range , ALAT and/or ASAT ≤2.5 x UNL , Alkaline Phosphatase ≤5 x UNL Adequate renal function ( within 4 week prior start treatment ) : calculate creatinine clearance ≥50 mL/min Patients must accessible treatment followup Written inform consent accord local Ethics Committee requirement Patients advance pulmonary disease cause ( oxygen dependent ) Peripheral neuropathy &gt; grade 2 whatever cause Serious disease recent myocardial infarction , clinical sign cardiac failure clinically significant arrythmias Evidence distant metastasis ( M1 ) Patients history breast cancer Patients history another malignancy ( except basal cell skin carcinoma carcinomainsitu uterine cervix ) within 5 year study entry Pregnant lactate woman , potentially fertile woman use adequate contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Large resectable breast cancer</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>Neoadjuvant therapy</keyword>
</DOC>